CERo Therapeutics Holdings, Inc.

Contributing Author

Recent Articles by CERo Therapeutics Holdings, Inc.

Jul-31	CERo Therapeutics Doses Second Acute Myeloid Leukemia Patient with CER-1236 CERO GlobeNewswire
Jun-23	CERo Therapeutics Holdings, Inc. Announces First Patient Completes Dose-Limiting Toxicity Observation Period with No Reported DLTs in Phase 1 Trial of CER-1236 CERO GlobeNewswire
Jun-17	CERo Therapeutics Holdings, Inc. Announces FDA Orphan Drug Designation Granted to CER-1236 for the Treatment of Acute Myeloid Leukemia (AML) CERO GlobeNewswire
Jun-11	CERo Therapeutics Holdings, Inc. Announces Reverse Stock Split CERO GlobeNewswire
Jun-06	CERo Therapeutics, Inc. Announces Option Exercise for Additional Series D Financing CERO GlobeNewswire
Jun-02	CERo Therapeutics Holdings, Inc. Announces Continued Enhancement of Intellectual Property Portfolio with Two Granted U.S. Patents and European Patent Application Allowance Regarding Company's Lead Compound CER-1236 CERO GlobeNewswire
May-30	CERo Therapeutics Holdings, Inc. Doses First Patient with CER-1236 in Phase 1 Clinical Trial for Acute Myeloid Leukemia and is Advancing Through Protocol-Defined Evaluations CERO GlobeNewswire
May-08	CERo Therapeutics Holdings, Inc. Regains Compliance with Nasdaq Listing Rule 5550(b)(1) CERO GlobeNewswire
Apr-30	CERo Therapeutics Holdings, Inc. Announces TriStar Centennial Medical Center as a Clinical Trial Site for its Phase 1 Clinical Trial of CER-1236 in Acute Myeloid Leukemia CERO GlobeNewswire